Ipidacrine Formulations for Sexual Dysfunction via Cholinesterase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations do not effectively address disorders of potency and other forms of sexual dysfunction, particularly those caused by decreased hormone production, chronic stress, anorgasmia, or delayed ejaculation.
Innovation Solution
Development of ipidacrine-based pharmaceutical formulations as a reversible cholinesterase inhibitor to enhance acetylcholine levels, influencing neuroregulatory functions and improving sexual behavior by regulating the cholinergic system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing pharmaceutical formulations are used for treating sexual dysfunction, then the treatment of other diseases (PNS, CNS disorders) is achieved, but the treatment of potency disorders and sexual activity disorders is not effective
Solution Approach 1:
The patent extends the application of ipidacrine from its traditional uses in treating PNS and CNS disorders to include sexual dysfunction, potency disorders, anorgasmia, and delayed ejaculation. This multi-functionality approach allows a single drug to address multiple unrelated conditions, thereby improving adaptability without compromising reliability through proper dosing regimens (3-300mg per dose)
Solution Approach 2:
The patent establishes specific dosage parameters (3-300mg per dose) and administration protocols for ipidacrine when used for sexual dysfunction, differentiating from its traditional dosing for neurological conditions. This parameter optimization ensures reliable treatment outcomes for the new indications while maintaining the drug's established safety profile
2Reliability
If cholinesterase inhibitors are administered to enhance acetylcholine levels, then neuroregulatory functions are improved, but the mechanism of action complexity increases
Solution Approach 1:
The patent utilizes acetylcholine as an intermediary substance that mediates the effect of ipidacrine on sexual function. By inhibiting cholinesterase, the drug increases acetylcholine levels, which then acts as the actual mediator to enhance neuroregulatory functions and improve sexual behavior, simplifying the direct mechanism while maintaining reliability
3Adaptability or versatility
If ipidacrine formulations are developed for sexual dysfunction, then new treatment options are created, but the formulation development complexity increases
Solution Approach 1:
The patent develops pharmaceutical formulations containing ipidacrine that can be used for multiple indications including sexual dysfunction, potency disorders, anorgasmia, and delayed ejaculation. This universal formulation approach creates new treatment options without requiring separate development processes for each indication, thereby maintaining ease of manufacture
Solution Approach 2:
The patent specifies dosage ranges (3-300mg per dose) and formulation types (tablets, capsules, solutions) for ipidacrine in sexual dysfunction treatment. These standardized parameter specifications simplify the formulation development process by providing clear guidance on effective concentrations and delivery methods, reducing development complexity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention is based on the use of ipidacrine to treat potency disorders and can be used in clinics for treating potency disorders related to the reduced production of reproductive gland hormones, disorders caused by chronic, including physical, stress, and also associated with spontaneously reduced sexual function, including anorgasmia or delayed ejaculation, and other sexual activity disorders not limiting the scope of the invention.